Abstract
Current guidelines recommend the use of dual or triple antithrombotic therapy for patients with atrial fibrillation (AF) undergoing a percutaneous coronary intervention (PCI). Dual therapy has demonstrated favorable safety outcomes without compromising efficacy endpoints compared to triple therapy in four major clinical trials. In this study, we created a Markov model to evaluate the cost-effectiveness of dual versus triple antithrombotic therapy using data from the RE-DUAL PCI clinical trial.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
